Osemitamab (TST001)
Gastric/Gastroesophageal Junction (G/GEJ) Cancer
Phase 2/3Active
Key Facts
Indication
Gastric/Gastroesophageal Junction (G/GEJ) Cancer
Phase
Phase 2/3
Status
Active
About Transcenta Therapeutics
A global, fully integrated biotherapeutics company developing differentiated and affordable antibody biologics for oncology and other serious diseases.
View full company profileAbout Transcenta Therapeutics
A global, fully integrated biotherapeutics company developing differentiated and affordable antibody biologics for oncology and other serious diseases.
View full company profile